RethinkPeptides
Peptide Doping and Sports

Growth Hormone Secretagogues and Anti-Doping

15 min read|March 22, 2026

Peptide Doping and Sports

20+ Banned GHS Compounds

WADA's 2026 prohibited list names over 20 growth hormone secretagogues by name, banning them at all times, in and out of competition.

WADA 2026 Prohibited List, Section S2.2.4

WADA 2026 Prohibited List, Section S2.2.4

Molecular structure of a growth hormone secretagogue peptide overlaid with a prohibited symbolView as image

Growth hormone secretagogues are among the most explicitly targeted compounds on the World Anti-Doping Agency's prohibited list. Unlike growth hormone itself, which requires complex biomarker-based testing, GHS compounds leave direct molecular traces in urine that laboratories can identify with high sensitivity. WADA's 2026 list names over 20 specific GHS compounds under section S2.2.4, covering both peptide-based GHRPs and non-peptide oral agents like ibutamoren (MK-677). For a broader overview of how anti-doping labs catch peptide use, see our guide on how peptide doping is detected.

Key Takeaways

  • WADA bans all growth hormone secretagogues at all times, both in and out of competition, under section S2.2.4 of the prohibited list
  • Judak et al. (2021) reviewed a decade of progress in LC-MS doping control for small peptides, establishing that GHRPs and GHS are now reliably detectable in urine[1]
  • Ibutamoren (MK-677) produces 22 identifiable metabolites, with detection windows extending to 96 hours after a single dose[2]
  • Anti-doping chemists have identified glycine-modified GHS designer analogs in seized doping materials, showing that clandestine manufacturers are already trying to evade detection[3]
  • Svensson et al. (1998) found MK-677 increased fat-free mass by approximately 3 kg over 8 weeks in obese subjects, but systematic reviews show GH elevation does not improve strength or aerobic capacity[4]
  • Ipamorelin is the only GHRP that does not raise ACTH or cortisol at GH-releasing doses, yet it remains equally prohibited[5]

What Are Growth Hormone Secretagogues?

Growth hormone secretagogues are compounds that stimulate the body's own production and release of growth hormone. They work by binding to the growth hormone secretagogue receptor (GHS-R), also known as the ghrelin receptor, on cells in the anterior pituitary and hypothalamus. Kojima et al. identified ghrelin as the endogenous ligand for this receptor in 1999, establishing that GHS compounds mimic a natural hormonal signal.[6] Liu et al. (2021) solved the cryo-EM structures of both ghrelin and ibutamoren bound to GHSR, revealing the molecular basis of how these compounds activate the receptor.[7]

Two main categories exist. Peptide-based GHRPs include GHRP-1, GHRP-2 (pralmorelin), GHRP-4, GHRP-5, GHRP-6, alexamorelin, hexarelin, and ipamorelin. These are typically short peptides of 4 to 7 amino acids that must be injected or administered nasally. Semenistaya et al. (2015) demonstrated that different GHRPs produce distinct metabolite profiles in urine after nasal administration, with ipamorelin (1-4) free acid persisting after the parent compound had cleared.[8]

Non-peptide GHS include oral agents like ibutamoren (MK-677), anamorelin, capromorelin, macimorelin, and tabimorelin. These molecules are not peptides in structure but activate the same GHS-R receptor. MK-677 has attracted particular attention because it can be taken as a pill, making it easier to use covertly than injectable peptides.

The critical distinction for anti-doping purposes: all of these compounds are purely exogenous. They do not exist naturally in the human body, so any detection in a biological sample is sufficient evidence of use.

Which GHS Compounds Does WADA Ban?

WADA classifies growth hormone secretagogues under Section S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics. Specifically, they fall under subsection S2.2.4, which covers growth hormone releasing factors. The prohibition applies at all times, meaning athletes cannot use these substances during competition or during training periods. For the complete breakdown of every banned peptide in sports, see WADA's prohibited peptide list.

The 2026 prohibited list explicitly names:

Growth hormone releasing hormone (GHRH) and analogs:

Growth hormone secretagogues (GHS) and mimetics:

  • Anamorelin
  • Capromorelin
  • Ibutamoren (MK-677)
  • Ipamorelin
  • Lenomorelin (ghrelin)
  • Macimorelin
  • Tabimorelin

GH-releasing peptides (GHRPs):

WADA includes the phrase "including but not limited to" before these lists. Novel GHS compounds, analogs, or designer variants are banned automatically, even if they are not named on the list. This "open" classification prevents manufacturers from creating slightly modified compounds to circumvent testing.

Why WADA Considers GHS a Doping Threat

The rationale for banning growth hormone secretagogues centers on their ability to elevate endogenous GH levels, which in turn raises IGF-1 (insulin-like growth factor 1). Elevated GH and IGF-1 can accelerate recovery from training and injury, increase lean body mass, and reduce body fat. These effects give athletes an unfair advantage, particularly in sports requiring power, speed, or rapid recovery between events.

GHS compounds present a specific concern because they can be harder to detect than exogenous GH. Injecting recombinant human GH introduces an identical molecule to what the body produces, requiring sophisticated isoform or biomarker tests. GHS compounds, by contrast, stimulate the body's own GH production, meaning GH levels rise through a natural pathway. Standard GH tests based on isoform ratios would miss this entirely.

Raun et al. (1998) demonstrated that ipamorelin releases GH with potency comparable to GHRP-6 (ED50 of 80 nmol/kg) while uniquely avoiding stimulation of ACTH and cortisol, even at doses 200 times above its effective GH-releasing dose.[5] This selectivity profile made ipamorelin particularly attractive for potential misuse because it would produce fewer detectable hormonal side effects than other GHRPs.

The detection challenge cuts both ways. While GHS-elevated GH cannot be caught by GH isoform tests, the GHS compounds themselves are exogenous molecules detectable by mass spectrometry. Anti-doping laboratories have developed increasingly sensitive methods to identify these substances directly.

What Athletes Actually Gain: The Evidence Gap

The appeal of GHS compounds rests on the assumption that raising GH and IGF-1 translates to better athletic performance. The clinical evidence tells a more complicated story.

Svensson et al. (1998) treated obese subjects with MK-677 at 25 mg/day for 8 weeks. The drug increased 24-hour GH secretion rate by 1.8-fold, raised IGF-1 levels, and increased fat-free mass by approximately 3 kg while boosting energy expenditure.[4] Murphy et al. (1998) showed MK-677 reversed diet-induced nitrogen wasting in healthy volunteers, increasing IGF-1 by 40% and producing sustained anabolic effects comparable to replacing normal caloric intake.[9]

These findings suggest real body composition effects. But the longest and largest MK-677 trial paints a different picture. Nass et al. (2008) randomized 65 healthy older adults to MK-677 or placebo for 12 months.[10] Fat-free mass increased by 1.1 kg with MK-677 versus a 0.5 kg decrease with placebo. IGF-1 rose 60.1% at 6 weeks and 72.9% at 12 months. But strength did not improve. And fasting glucose rose, with the dose reduced from 25 mg to 10 mg in five patients (6%) whose fasting blood glucose exceeded 140 mg/dL.

Cardaci et al. (2022) reported a case of a young male using both the SARM LGD-4033 and MK-677.[11] Body mass increased 6.0%, but total testosterone dropped 62.3%. The hormonal disruption is a reminder that GHS compounds produce systemic effects beyond the GH-IGF-1 axis.

Systematic reviews of exogenous GH in healthy young adults reach the same conclusion: GH administration increases lean body mass but does not improve strength or aerobic exercise capacity. GHS compounds, which produce smaller GH elevations than exogenous GH injection, face even weaker evidence for functional performance gains. The gap between body composition changes and actual athletic improvement is substantial, and no controlled study has demonstrated that any GHS compound improves competitive performance in healthy, trained athletes. For a deeper look at the performance question, see can growth hormone peptides build muscle.

How Anti-Doping Labs Detect GHS

LC-MS Methods for Peptide GHRPs

The primary detection strategy targets the GHS compounds and their metabolites directly in urine. Thomas et al. (2011) developed and validated a liquid chromatography-mass spectrometry (LC-MS) method for simultaneously detecting GHRP-1, GHRP-2, GHRP-4, GHRP-5, GHRP-6, alexamorelin, ipamorelin, and hexarelin in human urine.[12] Detection limits ranged from 0.2 to 1 ng/mL. In an excretion study with a single 10 mg oral dose of GHRP-2, the known metabolite (D-Ala-D-2-naphthylAla-L-Ala) was detectable for 20 hours. The intact drug was not observed in urine, emphasizing that metabolite-based detection is essential.

This metabolite-focused approach matters because many GHRPs degrade rapidly in the body. Semenistaya et al. (2015) studied five GHRPs after nasal administration and found that hexarelin and ipamorelin metabolized extensively, producing metabolite fragments that persisted longer than the parent compounds.[8] For ipamorelin, the (1-4) free acid metabolite was detectable in urine after the intact peptide had already cleared.

Comprehensive Screening Panels

Modern anti-doping laboratories no longer test for individual compounds one at a time. Chang et al. (2021) developed a single LC-HRMS (liquid chromatography-high resolution mass spectrometry) method using parallel reaction monitoring that simultaneously screens for 41 small peptides and 3 non-peptide GHS in a single urine sample.[13] This panel approach means athletes face detection risk for every known GHS variant in one test run. Judak et al. (2021) reviewed a decade of these analytical advances, documenting how detection sensitivity and coverage have steadily increased since the early 2010s.[1] To learn more about these detection technologies, see how peptide doping is detected in 2026.

MK-677 Detection

Ibutamoren (MK-677) deserves special attention because its oral bioavailability makes it uniquely accessible. Philip et al. (2022) characterized 22 metabolites of ibutamoren (17 phase I and 5 phase II) in thoroughbred horses, establishing the metabolic pathway that anti-doping laboratories use to detect it.[2] In humans, major metabolites are detectable for up to 96 hours after a single dose. The long detection window and extensive metabolite profile make MK-677 relatively straightforward to identify compared to short-acting injectable GHRPs.

The Designer GHS Problem

As detection methods improve, some manufacturers have begun modifying GHS structures to evade testing. Gajda et al. (2019) analyzed seized doping materials and identified glycine-modified analogs of known growth hormone secretagogues that had never been described in scientific literature.[3] These designer variants represented deliberate attempts to create compounds that would retain GH-releasing activity while producing different mass spectrometry signatures.

This finding illustrates an ongoing arms race between doping manufacturers and anti-doping laboratories. WADA's "including but not limited to" language on the prohibited list means these designer compounds are banned regardless of whether they are explicitly named. The increasing sensitivity of LC-HRMS methods and the expanding reference libraries of known metabolites make it progressively harder to introduce novel GHS compounds without detection.

GHS are far from the only peptide class under scrutiny. GLP-1 agonists face a more nuanced WADA status, while BPC-157 and TB-500 occupy their own anti-doping gray area.

The contamination problem adds another dimension. Sport Integrity Australia and other agencies have documented cases where supplements marketed for bodybuilding contained undeclared ibutamoren, sometimes without listing it on the label. Athletes who test positive face sanctions regardless of whether the ingestion was intentional, following WADA's strict liability principle.

Detection Windows and Practical Implications

Detection windows vary substantially between GHS compounds:

CompoundSample TypeDetection WindowSource
GHRP-2 metaboliteUrineUp to 20 hoursThomas et al., 2011
Hexarelin metabolitesUrineVariable, metabolite-dependentSemenistaya et al., 2015
Ipamorelin (1-4) free acidUrinePersists after parent clearsSemenistaya et al., 2015
Ibutamoren (MK-677)UrineUp to 96 hoursPhilip et al., 2022

These windows reflect single-dose studies. Chronic users likely accumulate metabolites that extend detection times, though this has not been as extensively studied. The short half-lives of injectable GHRPs (minutes to hours in blood) explain why urine testing and metabolite-based approaches are preferred for doping control.

The 2023 WADA Anti-Doping Testing Figures documented 288,865 samples analyzed globally with a 0.80% overall adverse finding rate. Growth hormone-related substances including GHS compounds contributed a growing share of peptide hormone findings compared to previous years.

Therapeutic Use Exemptions

WADA allows therapeutic use exemptions (TUEs) for prohibited substances when an athlete has a legitimate medical need. In the context of growth hormone secretagogues, TUE applications are exceptionally rare and difficult to obtain.

Macimorelin has FDA approval for diagnosing adult growth hormone deficiency. An athlete who required a GH stimulation test using macimorelin would need a TUE to undergo the diagnostic procedure. Tesamorelin has FDA approval for treating HIV-associated lipodystrophy. An athlete with this specific condition could theoretically apply for a TUE, though the approval process requires extensive documentation.

For compounds like GHRP-2, GHRP-6, ipamorelin, and ibutamoren, no approved pharmaceutical indications exist in most countries. Without a recognized medical indication and an approved pharmaceutical product, TUE applications for these compounds have virtually no pathway to approval.

The Bottom Line

Growth hormone secretagogues are banned at all times in sports under WADA section S2.2.4, covering both peptide GHRPs and non-peptide oral agents like MK-677. Clinical evidence shows these compounds raise GH and IGF-1 and can increase fat-free mass, but no controlled study has demonstrated improved strength or athletic performance in healthy subjects. Detection science has advanced to where multi-compound LC-HRMS panels screen for over 40 peptides simultaneously and metabolite profiling extends detection windows well beyond these compounds' short half-lives. The emergence of glycine-modified designer analogs in seized doping materials shows this remains an active and evolving field.

Frequently Asked Questions